Our lab’s vision is to develop an interdisciplinary approach to dementia research and care.
Dementia is a complex condition that crosses a number of clinical and scientific disciplines. We understand that a strong, multifaceted approach is required to make a significant impact in dementia research. This includes having a long-term coordinated approach to research.
The focus of our lab is to:
Australia, University of New South Wales, MBBS (Hons), BSc (Med), 2005
Australia, Royal Australasian College of Physicians, FRACP, 2012
Australia, University of Melbourne, PhD, 2015
Royal Melbourne Hospital
2022-2026, EL1 Investigator Grant – A diagnostic and therapeutic target in Alzheimer’s Disease, NHMRC
2020 – 2022, Part the Cloud Grant – S-adenosyl methionine for Alzheimer’s Disease, Alzheimer’s Association
2016-2019, Dementia Research Development Grant – Vascular Cognitive Risk Score: Quantifying the Vascular Burden in Alzheimer’s Disease, NHMRC
Scientific Co-Chair, Stroke Society of Australasia Annual Scientific Meeting, 2021
Member, Dementia Australia Scientific Panel, 2019-2021
Member, Acute Medical Writing Group – Stroke Clinical Guidelines – National Stroke Foundation, insert year(s)
Founding Co-Chair, Stroke Society of Australasia Emerging Stroke Clinicians and Scientists Special Interest Group, 2017-2022
1. Yassi N, Pase MP, Buckley RF, Rosenich E, Watson R, Maruff P, Lim YY. Cardiovascular Risk is Associated with Poorer Memory in Middle-aged Adults from the Healthy Brain Project. Journal of Alzheimer’s Disease. 2022. PMID: please insert
2. Kaffenberger T, Venkatraman V, Steward C, Thijs VN, Bernhardt J, Desmond PM, Campbell BCV, Yassi N. Stroke population-specific neuroanatomical CT-MRI brain atlas. Neuroradiology. 2022 PMID: 35094103
3. Yassi N, Zhao H, Churilov L, Campbell BCV, Wu T, Ma H, Cheung A, Kleinig T, Brown H, Choi P, Jeng JS, Ranta A, Wang HK, Cloud GC, Grimley R, Shah D, Spratt N, Cho DY, Mahawish K, Sanders L, Worthington J, Clissold B, Meretoja A, Yogendrakumar V, Ton MD, Dang DP, Phuong NTM, Nguyen HT, Hsu CY, Sharma G, Mitchell PJ, Yan B, Parsons MW, Levi C, Donnan GA, Davis SM. Tranexamic acid for intracerebral haemorrhage within 2 hours of onset: protocol of a phase II randomized placebo-controlled double-blind multicentre trial. Stroke and Vascular Neurology 2021
4. N. Yassi, S. Hilal, Y. Xia, Y. Y. Lim, R. Watson, H. Kuijf, C. Fowler, P. Yates, P. Maruff, R. Martins, D. Ames, C. Chen, C. C. Rowe, V. L. Villemagne, O. Salvado, P. M. Desmond and C. L. Masters. Influence of Comorbidity of Cerebrovascular Disease and Amyloid-beta on Alzheimer’s Disease. J Alzheimers Dis. 2020 73 PMID: 31884485
5. N. Yassi, L. Flicker and B. C. V. Campbell. Brain frailty and small vessel disease for stroke outcome prediction: Are we there yet? Neurology. 2020 94 PMID: 31882525
6. B. C. V. Campbell, P. J. Mitchell, L. Churilov, N. Yassi, T. J. Kleinig, R. J. Dowling, B. Yan, S. J. Bush, V. Thijs, R. Scroop, M. Simpson, M. Brooks, H. Asadi, T. Y. Wu, D. G. Shah, T. Wijeratne, H. Zhao, F. Alemseged, F. Ng, P. Bailey, H. Rice, L. de Villiers, H. M. Dewey, P. M. C. Choi, H. Brown, K. Redmond, D. Leggett, J. N. Fink, W. Collecutt, T. Kraemer, M. Krause, D. Cordato, D. Field, H. Ma, B. O’Brien, B. Clissold, F. Miteff, A. Clissold, G. C. Cloud, L. E. Bolitho, L. Bonavia, A. Bhattacharya, A. Wright, A. Mamun, F. O’Rourke, J. Worthington, A. A. Wong, C. R. Levi, C. F. Bladin, G. Sharma, P. M. Desmond, M. W. Parsons, G. A. Donnan, S. M. Davis and E.-I. T. P. investigators. Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial. JAMA. 2020 PMID: 32078683
7. H. Ma, B. C. V. Campbell, M. W. Parsons, L. Churilov, C. R. Levi, C. Hsu, T. J. Kleinig, T. Wijeratne, S. Curtze, H. M. Dewey, F. Miteff, C. H. Tsai, J. T. Lee, T. G. Phan, N. Mahant, M. C. Sun, M. Krause, J. Sturm, R. Grimley, C. H. Chen, C. J. Hu, A. A. Wong, D. Field, Y. Sun, P. A. Barber, A. Sabet, J. Jannes, J. S. Jeng, B. Clissold, R. Markus, C. H. Lin, L. M. Lien, C. F. Bladin, S. Christensen, N. Yassi, G. Sharma, A. Bivard, P. M. Desmond, B. Yan, P. J. Mitchell, V. Thijs, L. Carey, A. Meretoja, S. M. Davis, G. A. Donnan and E. Investigators. Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke. N Engl J Med. 2019 380 PMID: 31067369
8. Y. Y. Lim, N. Yassi, L. Bransby, M. Properzi and R. Buckley. The Healthy Brain Project: An Online Platform for the Recruitment, Assessment, and Monitoring of Middle-Aged Adults at Risk of Developing Alzheimer’s Disease. J Alzheimers Dis. 2019 68 PMID: 30909237
9. B. C. V. Campbell, P. J. Mitchell, L. Churilov, N. Yassi, T. J. Kleinig, R. J. Dowling, B. Yan, S. J. Bush, H. M. Dewey, V. Thijs, R. Scroop, M. Simpson, M. Brooks, H. Asadi, T. Y. Wu, D. G. Shah, T. Wijeratne, T. Ang, F. Miteff, C. R. Levi, E. Rodrigues, H. Zhao, P. Salvaris, C. Garcia-Esperon, P. Bailey, H. Rice, L. de Villiers, H. Brown, K. Redmond, D. Leggett, J. N. Fink, W. Collecutt, A. A. Wong, C. Muller, A. Coulthard, K. Mitchell, J. Clouston, K. Mahady, D. Field, H. Ma, T. G. Phan, W. Chong, R. V. Chandra, L. A. Slater, M. Krause, T. J. Harrington, K. C. Faulder, B. S. Steinfort, C. F. Bladin, G. Sharma, P. M. Desmond, M. W. Parsons, G. A. Donnan, S. M. Davis and E.-I. T. Investigators. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke. N Engl J Med. 2018 378 PMID: 35135319
10. B. C. Campbell, P. J. Mitchell, T. J. Kleinig, H. M. Dewey, L. Churilov, N. Yassi, B. Yan, R. J. Dowling, M. W. Parsons, T. J. Oxley, T. Y. Wu, M. Brooks, M. A. Simpson, F. Miteff, C. R. Levi, M. Krause, T. J. Harrington, K. C. Faulder, B. S. Steinfort, M. Priglinger, T. Ang, R. Scroop, P. A. Barber, B. McGuinness, T. Wijeratne, T. G. Phan, W. Chong, R. V. Chandra, C. F. Bladin, M. Badve, H. Rice, L. de Villiers, H. Ma, P. M. Desmond, G. A. Donnan, S. M. Davis and Extend-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. N Engl J Med. 2015 372
The SIMOA-HDX technology is a highly sensitive and automated biomarker platform which allows for the detection of proteins associated with dementia pathology in blood and other body fluids (e.g. spinal fluid). The detection of blood biomarkers such as neurofilament light chain, amyloid-ß and tau represents a major potential advance in the field of dementia, opening up the possibility of a blood test for dementia diagnosis. The SIMOA platform is also available for research collaborations in other neurological and non-neurological diseases.
Learn more about the SIMOA HD-X Service
Lucy Bradbury, SIMOA scientist
Associate Professor Nawaf Yassi
Associate Professor Rosie Watson – Lesley Vidaurre
S-adenosyl methionine (SAMe) is a natural compound which plays a key role in the homocysteine cycle. It is also a key substrate for multiple biochemical methylation pathways, including DNA methylation and methylation of PP2a, the primary tau phosphatase enzyme. Reduced methylation of PP2a has been shown to be associated with the development of Alzheimer’s disease pathology (particularly p-tau), and SAMe has been shown to attenuate this process in preclinical models. We are conducting a phase 2 trial using oral SAMe in patients will mild to moderate Alzheimer’s disease to investigate its effect on levels of p-tau in the disorder. SAMe could represent a simple, cheap and safe intervention for patients with Alzheimer’s disease and other tauopathies.
Assoc Prof Nawaf Yassi
Assoc Prof Rosie Watson
Dr Sarah Holper
Dr Paula Loveland
Dr Oneil Bhalala
Dr Jenny Yu
Dementia diagnosis is challenging. In Australia, the average time taken from the beginning of symptoms to a diagnosis of dementia is over 3 years, and this is longer in people living in regional or rural areas, or people from culturally and linguistically diverse backgrounds. Even when a diagnosis is made, there are cases where the diagnosis may be inaccurate due to overlap of clinical symptoms between different dementias, and due to a number of other medical and psychological conditions that can mimic dementia.
Brain scans and spinal fluid analysis can help improve diagnosis but are costly, limited in terms of access, and invasive in some cases. The possibility of a blood test supporting dementia diagnosis would revolutionise diagnosis and care for patients with or at risk of the condition.
In this study, we are implementing a blood-based diagnostic test for patients being assessed for dementia at the Royal Melbourne Hospital Cognitive, Dementia and Memory Service (CDAMS) Clinic. We will investigate the diagnostic accuracy of these blood tests, and their impact on clinician diagnostic confidence.